Orgenesis (ORGS) Competitors $1.39 -0.21 (-13.13%) As of 01/17/2025 03:42 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends ORGS vs. LSTA, CGTX, CVM, INKT, KALA, MRNS, UBX, DARE, VRCA, and MTEXShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Lisata Therapeutics (LSTA), Cognition Therapeutics (CGTX), CEL-SCI (CVM), MiNK Therapeutics (INKT), KALA BIO (KALA), Marinus Pharmaceuticals (MRNS), Unity Biotechnology (UBX), Daré Bioscience (DARE), Verrica Pharmaceuticals (VRCA), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Lisata Therapeutics Cognition Therapeutics CEL-SCI MiNK Therapeutics KALA BIO Marinus Pharmaceuticals Unity Biotechnology Daré Bioscience Verrica Pharmaceuticals Mannatech Orgenesis (NASDAQ:ORGS) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do analysts rate ORGS or LSTA? Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 304.31%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, ORGS or LSTA? Lisata Therapeutics has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$530K12.59-$55.36MN/AN/ALisata TherapeuticsN/AN/A-$20.84M-$2.51-1.48 Which has more volatility & risk, ORGS or LSTA? Orgenesis has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Is ORGS or LSTA more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Lisata Therapeutics N/A -51.19%-45.16% Does the MarketBeat Community prefer ORGS or LSTA? Lisata Therapeutics received 13 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 93.33% of users gave Lisata Therapeutics an outperform vote. CompanyUnderperformOutperformOrgenesisOutperform Votes1100.00% Underperform VotesNo VotesLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67% Does the media refer more to ORGS or LSTA? In the previous week, Lisata Therapeutics had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Lisata Therapeutics and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score. Company Overall Sentiment Orgenesis Neutral Lisata Therapeutics Neutral Do insiders and institutionals hold more shares of ORGS or LSTA? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryLisata Therapeutics beats Orgenesis on 10 of the 14 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.67M$6.50B$5.34B$9.12BDividend YieldN/A2.95%5.37%4.01%P/E RatioN/A4.3657.4613.13Price / Sales12.59310.771,272.2275.82Price / CashN/A22.8736.6632.72Price / Book-0.214.964.884.58Net Income-$55.36M$154.90M$118.05M$224.83M7 Day Performance-7.95%1.35%1.45%2.37%1 Month Performance6.92%0.41%2.50%4.40%1 Year PerformanceN/A3.08%25.79%20.10% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$1.39-13.1%N/AN/A$6.67M$530,000.000.00150LSTALisata Therapeutics3.0146 of 5 stars$3.67-1.6%$15.00+308.7%+25.8%$30.81MN/A-1.4630Positive NewsCGTXCognition Therapeutics2.5288 of 5 stars$0.74-2.7%$8.30+1,021.5%-70.4%$30.75MN/A-0.7620Gap DownCVMCEL-SCIN/A$0.41-2.4%N/A-83.4%$30.70MN/A-0.7243Gap UpINKTMiNK Therapeutics2.4589 of 5 stars$0.77+5.9%$6.50+739.9%+0.0%$30.67MN/A-1.9830Gap UpKALAKALA BIO4.1002 of 5 stars$6.55-3.8%$15.00+129.0%-2.3%$30.20M$3.89M-0.5330Negative NewsMRNSMarinus Pharmaceuticals4.606 of 5 stars$0.54+0.8%$4.79+784.4%-94.4%$29.88M$31.47M-0.22110Analyst ForecastUBXUnity Biotechnology4.4282 of 5 stars$1.72-3.9%$7.33+326.4%+3.6%$28.98M$240,000.00-1.3160DAREDaré Bioscience1.2681 of 5 stars$3.33+6.7%$24.00+620.7%-10.2%$28.97M$1.88M-5.6430News CoveragePositive NewsVRCAVerrica Pharmaceuticals4.0806 of 5 stars$0.64-3.8%$9.50+1,396.1%-88.5%$28.96M$9.21M-0.3540MTEXMannatech0.4386 of 5 stars$15.17+1.3%N/A+33.6%$28.60M$121.55M-18.73250Analyst ForecastGap Down Related Companies and Tools Related Companies Lisata Therapeutics Alternatives Cognition Therapeutics Alternatives CEL-SCI Alternatives MiNK Therapeutics Alternatives KALA BIO Alternatives Marinus Pharmaceuticals Alternatives Unity Biotechnology Alternatives Daré Bioscience Alternatives Verrica Pharmaceuticals Alternatives Mannatech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORGS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.